Resources in Our Area

Austin Liver Support Group

Central Texas Regional Blood and Tissue Center - (Directions)
4300 N. Lamar Boulevard
Austin, TX 78701

Meets: third Tuesday of every month, noon-2pm

Contact Janet Byer for more information.

Email: Austin Liver Support Group

Liver Health Today Magazine (formerly Hepatitis Magazine)

Various locations

Contact Brian Tutt for more information.

Web: www.hepatitismagazine.com/groups.asp

Parent Support Group

Texas Children's Liver Center
Houston, TX

Contact Harriet Spain for more information.

Phone: 713-206-6807
Web: www.texaskidsliver.org
Email: Parent Support Group

PBC_Digest: An Online Support Group

The Primary Billiary Cirrhosis Organization aka PBCers is a wonderful source of support and education for primary biliary cirrhosis (PBC) patients, family members, friends and other autoimmune liver disease patients. Formed in 1996, the PBCers is the largest online PBC support group with almost 3,000 members worldwide.

As a group, we discuss medical information, pain management, medications, research, ask questions, transplantation, vent our anger & fears, speak freely on the ups and downs of daily living, share our personal experiences and build lasting friendships.

Read the guidelines for joining.

Contact Linie Moore for more information.

Web: www.pbcers.org

St. Luke's Liver Center Support Groups

Web: www.texasliver.org/community/groups/houston.htm

Advanced Liver Therapies

St. Luke's Center for Liver Disease
Houston, TX 77030

PBC (Primary Biliary Cirrhosis)

1. Modified bile acid (INT-747 study drug) for subjects currently taking URSO

Main Inclusion criteria: Stable dose of ursodeoxycholic acid (URSO®, UDCA) for at least 6 months prior to screening Two of the following 3 criteria must be present: Elevated Alk phos, liver bx consistent with PBC or +AMA.

Main Exclusion Criteria: Administration of the following drugs at any time during the 3 months prior to screening for the study: colchicine, methotrexate, azathioprine, or systemic corticosteroids.

2. Modified bile acid (INT-747 study drug) for subjects for patients not taking URSO

Main Inclusion criteria: dose of ursodeoxycholic acid (URSO®, UDCA) for at least 6 months prior to screening OR no exposure to URSO within the past 3 monthsTwo of the following 3 criteria must be present: Elevated Alk phos, liver bx consistent with PBC or +AMA.

Main Exclusion Criteria: Administration of the following drugs at any time during the 3 months prior to screening for the study: colchicine, methotrexate, azathioprine, URSO, or systemic corticosteroids.

HEP C

1. (Naïve or non-responders) – Yeast based immune system stimulant (inj) + peg + rib.

Main Inclusion Criteria: Chronic hepatitis C infection with genotype 1Non-Responder Definition:• Poor responders - a subset of non-responders who achieved > 1 log10 but < 2 log10 reduction in HCV RNA after a minimum of 12 weeks of therapy.• Partial responders – a subset of non-responders who achieve at least a 2 log10 reduction in HCV RNA by 12 weeks, but do not achieve an end of treatment response

Main Exclusion Criteria:• Null response to prior IFN plus ribavirin therapy, defined as received at least 12 weeks of interferon-based treatment with < 1 log10 reduction in viral load;• Subjects treated with more than 1 complete hepatitis C regimen • Subjects that required a significant dose reductions• Subjects that required growth factors • Body weight >275 pounds• Cirrhosis

2. Hep C – (Effect of treatment with Pegasys®/Copegus® with or without concomitant pioglitazone (Actos®) on early viral kinetics in treatment-naïve patients with chronic hepatitis C (genotype 1 HCV infection) and insulin resistance)

Main Inclusion Criteria:• Naïve and geno 1• Insulin resistance (i.e. fasting blood glucose > 100 mg/dL, or fasting insulin > 10 IU/mL)• Has not received insulin treatment during the prior 2 weeks and has a fasting plasma glucose < 240 mg/dL. Oral hypoglycemic agents are allowed if stable for ≥ 2 months prior to randomization.

Main Exlusion Criteria: Type-1 diabetes or cirrhosis.

Contact Jana Lee, RN, CCRC; Gerald Brown, RN for more information.

Phone: 832-355-8966 (832-683-5814)
Email: Advanced Liver Therapies

ClinicalTrials.gov

A service of the U.S. National Insitutes of Health, ClinicalTrials.gov provides regularly updated information about federally and privately supported clinical research in human volunteers. ClinicalTrials.gov gives you information about a trial's purpose, who may participate, locations, and phone numbers for more details. The information provided on ClinicalTrials.gov should be used in conjunction with advice from health care professionals.

Fatty Liver/Hepatitis C Clinical Trial

Brooke Army
Fort Sam Houston, TX

Contact Stephen A Harrison, MD (Brooke Army Medical Center) for more information.

Phone: 210-916-5553
Web: http://clinicaltrials.gov/ct/show/NCT00207311;jsessionid=13773F43841DD51AEF3451F2AEB9B30C?order=49

Rare Cholestatic Liver Disease Clinical Study

Do you or somone you know suffer with a rare cholestatic liver disease. Do you have questions or concerns and want to know more? This NIH funded pediatric trial goes up to 25 years of age. It is called the CLiC trial.

Phone: 832-824-3754
Web: rarediseasesnetwork.epi.usf.edu/clic/index.htm

There are no organizations in this category.

There are no organizations in this category.